PubMed
Interestingly, chronic activation of the immune-inflammatory pathways could play a possible role in HPA axis hypofunction (Papadopoulos and Cleare 2012)
Preclinical studies have shown that GLP-1 receptor agonism can attenuate alcohol-induced locomotor stimulation and accumbal dopamine release, reduce nicotine-associated reward behaviors, and suppress cocaine seeking or self-administration in rodent models [18-21]
Unlike the other weight loss injections, that are GLP-1 receptor agonists, it has a powerful double action, being a GLP-1 and GIP receptor agonist." Dorianne Green, Medical Writer Clinical studies highlight impressive results: average weight losses of 15% at 5 mg, 19% at 10 mg, and 21% at 15 mg
We offer insight into why obesity isnt always a choice
If youre considering semaglutide or tirzepatide and want guidance tailored to your health history, a brief assessment can help clarify your options